Abstract
Nanotechnology has emerged as a promising strategy to enhance the therapeutic efficacy of anti-cancer drugs. Traditional cancer treatments often face limitations such as poor bioavailability, toxicity, and resistance. Nanotechnology provides innovative solutions by utilizing nanoscale materials to improve the delivery, effectiveness, and targeting of anti-cancer drugs. This article explores the role of nanotechnology in improving drug bioavailability, targeting specific tumor sites, minimizing side effects, and overcoming resistance mechanisms. The application of nanocarriers, such as liposomes, dendrimers, and nanoparticles, offers new avenues in precision cancer therapy. Furthermore, it discusses the clinical challenges and future directions for integrating nanotechnology into cancer treatment.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.